Disease · MONDO_0015459
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Chemo + EBV-CTL vs Chemo Only: deaths from any cause | 16 of 163 | 8 of 162 | 325 | NCT02578641 | Trial comparisons |
| Chemo + EBV-CTL vs Chemo Only: serious adverse events | 68 of 163 | 46 of 162 | 325 | NCT02578641 | Trial comparisons |
| Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: Number of Participants Experiencing an Adverse Event(AE) | 143 of 143 | 146 of 146 | 289 | NCT03581786 | Trial comparisons |
| Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: deaths from any cause | 67 of 143 | 47 of 146 | 289 | NCT03581786 | Trial comparisons |
| Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: serious adverse events | 62 of 143 | 64 of 146 | 289 | NCT03581786 | Trial comparisons |
| Spartalizumab 400 mg Q4W vs Chemotherapy: Overall Response Rate (ORR) as Per RECIST v 1.1 | 15 of 82 | 13 of 40 | 122 | NCT02605967 | Trial comparisons |
| Docetaxel /Cisplatin/5-FU vs Cisplatin/5-FU: Number of Participants With Complete Response (CR) | 1 of 50 | 0 of 25 | 75 | NCT00565448 | Trial comparisons |
| Cisplatin/5-FU vs Docetaxel /Cisplatin/5-FU: serious adverse events | 11 of 25 | 20 of 50 | 75 | NCT00565448 | Trial comparisons |
| CC-486 200 mg vs CC-486 300 mg: deaths from any cause | 4 of 6 | 18 of 30 | 36 | NCT02269943 | Trial comparisons |
| CC-486 200 mg vs CC-486 300 mg: serious adverse events | 4 of 6 | 12 of 30 | 36 | NCT02269943 | Trial comparisons |
| Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years vs Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years: deaths from any cause | 12 of 13 | 2 of 2 | 15 | NCT02756845 | Trial comparisons |
| Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years vs Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years: serious adverse events | 5 of 13 | 1 of 2 | 15 | NCT02756845 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Overall Survival (OS) | 8 of 11 | 4 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Distant Metastases | 2 of 11 | 1 of 4 | 15 | NCT04458909 | Trial comparisons |
Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Number of Participants With Complete or Partial Response (Objective Response Rate) Through the End of Cycle 6 Determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | 4 of 11 | 0 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Progression-free Survival (PFS) | 3 of 11 | 3 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Number of Participants With Grade 3 or Higher Adverse Events (AEs) | 10 of 11 | 2 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): Locoregional Failure | 6 of 11 | 0 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): deaths from any cause | 3 of 11 | 0 of 4 | 15 | NCT04458909 | Trial comparisons |
| Arm I (Nivolumab, Gemcitabine, Cisplatin / Carboplatin) vs Arm II (Gemcitabine, Cisplatin / Carboplatin): serious adverse events | 10 of 11 | 2 of 4 | 15 | NCT04458909 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015459/comparisons